Swiss stocks closed higher on Tuesday, with the benchmark Swiss Market Index (SMI) gaining 1.55%. The advance was led by online pharmacy DocMorris, which raised its growth outlook for 2026 and announced a key profitability milestone.
DocMorris lifts guidance after strong quarter
DocMorris, a Swiss-based online pharmacy that operates across Europe, said third-quarter revenue rose to 327.4 million Swiss francs. That performance prompted the company to raise its 2026 external revenue growth guidance to a range of 12.5% to 15%, up from its previous forecast of 9% to 13%.
More significant than the sales beat, the company said it achieved its targeted earnings before interest, taxes, depreciation, and amortization (EBITDA) breakeven during the quarter. EBITDA is a common measure of a company's operational profitability, and reaching breakeven is a milestone for a business that has been investing heavily in growth.
For everyday investors, the upgrade signals that DocMorris's strategy of expanding its online pharmacy business is starting to pay off. The company has been spending on marketing, logistics, and digital infrastructure to capture a larger share of the European pharmacy market, and the new guidance suggests management sees a clearer path to sustained profitability.
Calm inflation data supports the market
The broader market also drew support from benign inflation signals. Switzerland's producer and import prices rose 0.3% month-on-month in September, but were down 0.2% compared with the same month last year. Producer prices measure what manufacturers pay for raw materials and other inputs, while import prices track the cost of goods brought into the country.
Year-on-year declines in these price measures suggest that inflationary pressures in Switzerland remain muted. That is generally positive for equities because it reduces the likelihood that the Swiss National Bank will need to tighten monetary policy aggressively. Lower inflation also helps preserve consumers' purchasing power, which can support spending and corporate earnings.
The calm inflation backdrop contrasts with some other major economies, where price pressures have been more stubborn. For Swiss investors, the data reinforces a picture of a relatively stable economic environment.
What it means for investors
For investors in Swiss equities, the day's move highlights how a single company's earnings update can move the entire index. DocMorris is a mid-sized stock, but its positive news helped lift sentiment across the market.
The company's raised guidance is a signal that the online pharmacy sector is maturing. As more consumers shift to digital healthcare services, companies like DocMorris are positioned to benefit. However, investors should note that the company is still in a growth phase, and profitability is only just emerging. Future performance will depend on whether it can maintain revenue growth while controlling costs.
For those with broader exposure to Swiss stocks, the SMI's gain reflects a combination of solid corporate news and a supportive macro backdrop. The index includes many multinational companies, so global economic conditions and currency movements also play a role.
Investors will likely watch DocMorris's next quarterly results to see if the company can sustain its momentum. They may also keep an eye on Swiss inflation data, as any significant uptick could change the central bank's policy stance.
Related coverage: For more on how inflation and corporate earnings are moving markets, see our reports on hot PPI and AI debt jitters and regional banks' mixed earnings.
Also, for context on the Swiss financial sector, read about the Credit Suisse bonus clawback ruling.
